| ALLO Market Cap History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the ALLO market cap history going back to 10/11/2018:
Also see: ALLO Shares Outstanding History and ALLO YTD Return |
ALLO Market Cap History — Allogene Therapeutics Capitalization Over Time
As of 8/10/2026 Allogene Therapeutics has a market cap of 725.53 million. Investors often follow the ALLO market cap history to compare the size of the company over time.
This page shows ALLO market capitalization trends over time, with 32 market cap datapoints presented, dating back to 10/11/2018.
| ALLO Market Cap History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ALLO Historical Market Cap: -15.99% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ALLO Stock Price Chart |
| About Allogene Therapeutics Inc |
| Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. Co. is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. We show 32 historical shares outstanding datapoints in our ALLO shares outstanding history coverage, used to compute ALLO market cap on those dates. Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing ALLO market cap history over the course of time is important for investors interested in comparing ALLO's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of ALLO versus a peer is one thing; comparing ALLO market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like ALLO can fluctuate over the course of history. With this page we aim to empower investors researching ALLO by allowing them to research the ALLO market cap history. |
| ALLO Current Stock Quote |
Quotes delayed 20 minutes  Free ALLO Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: The Importance of Market Cap | |
|
Video: The Importance of Market Cap
| ALLO Share Performance |
| Market Cap Peers |
| Allogene Therapeutics (ALLO) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:
ALLR Market Cap History ALMS Market Cap History ALNA Market Cap History ALNY Market Cap History ALOG Market Cap History ALPN Market Cap History ALQA Market Cap History ALRN Market Cap History ALT Market Cap History ALTS Market Cap History More Healthcare companies » |
ALLO Market Cap History | www.MarketCapHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in MarketCapHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
